Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 115

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 115
---
 medical technology, biotechnology,
diagnostic and pharmaceutical industries. Renovaro Cube may become party to, or threatened with, future adversarial proceedings or litigation
regarding intellectual property rights with respect to its products, including interference proceedings before the United Kingdom Intellectual Property Office, the European Patent Office, the United States Patent and Trademark Office and similar bodies in other jurisdictions.
Third parties may assert infringement claims against Renovaro Cube based on existing patents or patents that may be issued in the future.

If Renovaro
Cube is found to infringe, misappropriate, or otherwise violate a third party’s intellectual property rights, it could be required
to obtain a license from such third party to continue developing, marketing, selling and distributing Renovaro Cube’s products,
or to cease using the infringing technology. However, Renovaro Cube may not be able to obtain any required license on commercially reasonable
terms or at all. Even if Renovaro Cube were able to obtain a license, it could be non-exclusive, thereby giving Renovaro Cube’s
competitors access to the same technologies licensed to Renovaro Cube. In addition, Renovaro Cube could be found liable for monetary damages,
including treble damages if it is found to have willfully infringed a patent and attorneys’ fees if the court finds the case to
be exceptional. A finding of infringement, misappropriation, or other violation could prevent Renovaro Cube from commercializing its products
or force Renovaro Cube to cease some of its operations, which could materially harm its business. Claims that Renovaro Cube has misappropriated
the confidential information or trade secrets of third parties could have a similar negative impact on Renovaro Cube’s business.

Even if
resolved in Renovaro Cube’s favor, litigation or other legal proceedings relating to intellectual property claims may cause Renovaro
Cube to incur significant expenses and could distract Renovaro Cube’s personnel from their normal responsibilities. Such litigation
or proceedings could substantially increase Renovaro Cube’s operating losses and reduce the resources available for development
activities or any future sales, marketing, or distribution activities. Renovaro Cube may not have sufficient financial or other resources
to conduct such litigation or proceedings adequately. Some of Renovaro Cube’s competitors may be able to sustain the costs of such
litigation or proceedings more effectively than Renovaro Cube can because of their greater financial resources and more mature and developed
intellectual property portfolios. Uncertainties resulting from the initiation and continuation of